Literature DB >> 2573554

Insulin regulation of lipolysis in nondiabetic and IDDM subjects.

M D Jensen1, M Caruso, V Heiling, J M Miles.   

Abstract

To determine whether insulin regulation of lipolysis is abnormal in subjects with poorly controlled insulin-dependent diabetes mellitus (IDDM), free-fatty acid flux ([1-14C]palmitate) was measured under conditions ranging from complete insulin withdrawal to hyperinsulinemia. Seven nondiabetic and seven IDDM subjects were studied with the pancreatic clamp technique to control plasma insulin, growth hormone, and glucagon concentrations at the desired levels. Preliminary studies were performed to validate the experimental design. The palmitate flux response to insulin withdrawal (2.5 +/- 0.2 vs. 2.5 +/- 0.2 mumol.kg-1.min-1) and maximally antilipolytic insulin concentrations (0.17 +/- 0.02 vs. 0.23 +/- 0.03 mumol.kg-1.min-1) were not different in nondiabetic and IDDM subjects, respectively. In contrast, IDDM subjects required significantly greater plasma free-insulin concentrations to result in equivalent suppression of palmitate flux compared with nondiabetic subjects. Lipolysis was found to be very sensitive to insulin in nondiabetic humans, with half-maximal suppression occurring at plasma free-insulin concentrations of approximately 12 pM (less than 2 microU/ml). We conclude that adipose tissue lipolysis is normally exquisitely sensitive to insulin and that sensitivity, but not responsiveness to insulin, is impaired in poorly controlled IDDM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573554     DOI: 10.2337/diab.38.12.1595

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  59 in total

1.  Fatty acid oxidation in human skeletal muscle.

Authors:  Michael D Jensen
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Phenylalanine kinetics in human adipose tissue.

Authors:  S W Coppack; M Persson; J M Miles
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 3.  Diet and exercise for weight loss: a review of current issues.

Authors:  Jeff S Volek; Jaci L Vanheest; Cassandra E Forsythe
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

4.  Pioglitazone increases non-esterified fatty acid clearance in upper body obesity.

Authors:  S Shadid; M D Jensen
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

5.  No, the glycaemic target in the critically ill should not be < or = 6.1 mmol/l.

Authors:  J M Miles; M M McMahon; W L Isley
Journal:  Diabetologia       Date:  2007-12-20       Impact factor: 10.122

6.  Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics.

Authors:  Xuewen Wang; Faidon Magkos; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Bettina Mittendorfer
Journal:  Eur J Endocrinol       Date:  2012-05-22       Impact factor: 6.664

7.  Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome.

Authors:  Uche Ezeh; Zorayr Arzumanyan; Daria Lizneva; Ruchi Mathur; Yen-Hao Chen; Raymond C Boston; Y-D Ida Chen; Ricardo Azziz
Journal:  Hum Reprod       Date:  2019-02-01       Impact factor: 6.918

8.  Errors in measuring plasma free fatty acid concentrations with a popular enzymatic colorimetric kit.

Authors:  Yilin Song; Lianzhen Zhou; Michael D Jensen
Journal:  Clin Biochem       Date:  2019-01-29       Impact factor: 3.281

9.  The effects of different plasma insulin concentrations on lipolytic and ketogenic responses to epinephrine in normal and type 1 (insulin-dependent) diabetic humans.

Authors:  A Avogaro; A Valerio; L Gnudi; A Maran; M Miola; E Duner; C Marescotti; E Iori; A Tiengo; R Nosadini
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

Review 10.  Role of body fat distribution and the metabolic complications of obesity.

Authors:  Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.